On March 11, China's first innovative drug　　for precise postoperative assessment of differentiated thyroid cancer was launched.Human thyroid-stimulating hormone beta (Zesuning) for injection at the First Affiliated Hospital of Zhejiang University School of MedicineThe first prescription was issued by Jiangsu Provincial People's Hospital .

Thyroid cancer is one of the fastest-growing solid tumors in recent years. Differentiated thyroid cancers, such as papillary carcinoma and follicular carcinoma, account for over 90% of cases. These tumors generally have a good prognosis, with a 10-year survival rate exceeding 90%. However, a high survival rate does not mean "no management is needed." Studies show that approximately 10%-30% of patients still face the risk of recurrence or metastasis during postoperative follow-up. Therefore, regular and standardized postoperative follow-up to monitor for residual lesions or signs of recurrence is crucial for improving the long-term quality of life for these patients.

For patients who have undergone total resection of differentiated thyroid cancer, sTg testing and whole-body radioactive iodine scintigraphy (WBS) are important and precise assessment methods. To prepare for these tests, patients need to discontinue thyroid hormone replacement therapy in advance, causing an increase in thyroid-stimulating hormone (TSH). During the discontinuation period, patients quickly enter a state of hypothyroidism, experiencing a series of hypothyroid symptoms such as fatigue, cold intolerance, low mood, slow reaction time, and facial edema, severely impacting their daily work, life, and emotional well-being. Some patients even postpone or abandon follow-up examinations due to intolerance to discontinuing medication, leading to poor adherence and making early detection of recurrence difficult. Clinically, follow-up examinations require elevated TSH, but increasing TSH often comes at the cost of patients' quality of life. This contradiction necessitates a post-operative management approach for thyroid cancer that breaks through the traditional "discontinuation of medication" method.

In June of last year, Merck entered into a collaboration agreement with Zaijing Pharmaceuticals, acquiring exclusive commercialization rights in mainland China for Zassinin, a recombinant human thyroid-stimulating hormone for injection developed in-house. Zassinin is approved in China for the collaborative diagnosis of differentiated thyroid cancer (DTC) patients during follow-up after total or near-total thyroidectomy, using serum thyroglobulin (Tg) testing, with or without radioactive iodine (³I) whole-body scintigraphy (WBS).

https://finance.eastmoney.com/a/202603133671243136.html